Patents by Inventor Vincent Giguere
Vincent Giguere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6806359Abstract: The present invention provides substantially pure DNA's comprised of sequences which encode proteins having the hormone-binding and/or transcription-activating characteristics of a glucocorticoid receptor, a mineralocorticoid receptor, or a thyroid hormone receptor. The invention also provides various plasmids containing receptor sequences which exemplify the DNA's of the invention. The invention further provides receptor proteins, including modified functional forms thereof, expressed from the DNA's (or mRNA's) of the invention. In addition to novel receptor DNA, RNA and protein compositions, the present invention involves a bioassay for determining the functionality of a receptor protein. By using our bioassay system we have discovered that a necessary and sufficient condition for activation of transcription of a gene (G), whose transcription is activated by hormones complexed with receptors, is the presence of the hormone and its receptor in the cell (C) where (G) is located.Type: GrantFiled: June 5, 1995Date of Patent: October 19, 2004Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 6794160Abstract: The present invention provides substantially pure DNA's comprised of sequences which encode proteins having the hormone-binding and/or transcription-activating characteristics of a glucocorticoid receptor, a mineralocorticoid receptor, or a thyroid hormone receptor; various plasmids containing receptor sequences which exemplify these DNA's; receptor proteins, including modified functional forms thereof, expressed from these DNA's (or mRNA's); and a bioassay for determining the functionality of a receptor protein. Use of this bioassay has led to the discovery that a necessary and sufficient condition for activation of transcription of a gene (G), whose transcription is activated by hormones complexed with receptors, is the presence of the hormone and its receptor cell (C) where (G) is located. As a result, two new methods for producing desired proteins in genetically engineered cells were discovered.Type: GrantFiled: June 5, 1995Date of Patent: September 21, 2004Inventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Publication number: 20030028910Abstract: The present invention relates to a transgenic non-human mammal whose germ cells and somatic cells contain a knockout mutation in DNA encoding orphan nuclear receptor ERR&agr;. More specifically, the invention relates to knockout mice whose germ cells and somatic cells contain a knockout mutation in DNA encoding orphan nuclear receptor ERR&agr;. The invention further relates to such knockout non-human mammals which express an ERR&agr; gene which is different from the endogenous gene which was disrupted. In a particular embodiment, the invention relates to a transgenic mouse having its endogenous ERR&agr; gene disrupted and expressing human ERR&agr;. As well, the invention relates to cell lines in which ERR&agr; activity (and/or level) has been inactivated or augmented. The invention further relates to uses and methods of the transgenic animals of the present invention to select agents which modulate the expression and/or activity of ERR&agr;.Type: ApplicationFiled: August 8, 2001Publication date: February 6, 2003Inventors: Vincent Giguere, Robert Sladek, Jiang-Ming Luo
-
Patent number: 5710004Abstract: Novel members of the steroid/thyroid superfamily of receptors are described. DNA sequences encoding same, expression vectors containing such DNA and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel receptors of the invention, and various uses thereof.Type: GrantFiled: August 7, 1996Date of Patent: January 20, 1998Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, David J. Mangelsdorf, Estelita S. Ong, Anthony E. Oro, Uwe K. Borgmeyer, Vincent Giguere, Tso-Pang Yao
-
Patent number: 5696233Abstract: Novel members of the steroid/thyroid superfamily of receptors are described. DNA sequences encoding same, expression vectors containing such DNA and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel receptors of the invention, and various uses thereof.Type: GrantFiled: June 5, 1995Date of Patent: December 9, 1997Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, David J. Mangelsdorf, Estelita S. Ong, Anthony E. Oro, Uwe K. Borgmeyer, Vincent Giguere, Tso-Pang Yao
-
Patent number: 5606021Abstract: The present invention provides recombinant proteins having the hormone-binding and/or transcription-activating characteristics of a mineralocorticoid receptor. The invention also provides proteins expressed from recombinant DNA encoding a naturally occurring receptor having the hormone-binding and/or transcription-activating characteristics of a mineralocorticoid receptor.Type: GrantFiled: December 17, 1993Date of Patent: February 25, 1997Assignee: The Salk Institute For Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 5599904Abstract: A novel retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid phRAR1, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera are constructed by exchanging functional domains between the glucocorticoid, the mineralocorticoid, the estrogen-related, the thyroid and the retinoic acid receptors. In addition, a novel method for identifying functional ligands for receptor proteins is disclosed. The method, which takes advantage of the modular structure of the hormone receptors and the idea that the functional domains may be interchangeable, replaces the DNA-binding domain of a putative novel receptor with the DNA-binding domain of a known receptor such as the glucocorticoid receptor. The resulting chimeric construction, when expressed in cells, produces a hybrid receptor whose activation of a ligand-(e.g.Type: GrantFiled: March 3, 1992Date of Patent: February 4, 1997Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere
-
Patent number: 5597705Abstract: The present invention provides a recombinant expression system for production of functional thyroid hormone receptor protein(s). The invention also provides a method to produce thyroid hormone receptor protein(s) by culturing the cells of the invention recombinant expression system. Also provided are thyroid hormone receptor protein(s) produced by the invention method. In addition, the present invention provides recombinant DNAs comprised of sequences which encode proteins having the hormone-binding and/or transcription-activating characteristics of a thyroid hormone receptor. The invention also provides various plasmids containing receptor sequences which exemplify the DNAs of the invention. The invention further provides complementary mRNAs, cells transformed with invention DNAs, and nucleic acid probes derived from invention DNAs.Type: GrantFiled: December 10, 1993Date of Patent: January 28, 1997Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 5571692Abstract: DNA encoding a human retinoic acid receptor alpha protein is disclosed. The sequence of the receptor is encoded by the cDNA insert of plasmid phRAR1, which has been deposited with ATCC. Methods employing chimeric receptors derived from the retinoic acid receptor are illustrated which demonstrate that the ligand for the new receptor is the retinoid, retinoic acid.Type: GrantFiled: December 16, 1993Date of Patent: November 5, 1996Assignee: The Salk Institute For Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere
-
Patent number: 5571696Abstract: Novel members of the steroid/thyroid superfamily of receptors are described. DNA sequences encoding same, expression vectors containing such DNA and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel receptors of the invention, and various uses thereof.Type: GrantFiled: November 2, 1994Date of Patent: November 5, 1996Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, David J. Mangelsdorf, Estelita S. Ong, Anthony E. Oro, Uwe K. Borgmeyer, Vincent Giguere, Tso-Pang Yao
-
Patent number: 5548063Abstract: A human retinoic acid receptor alpha protein is disclosed. The receptor is encoded by the cDNA insert of plasmid phRAR1, which has been deposited with ATCC. Methods employing chimeric receptors derived from the retinoic acid receptor are illustrated which demonstrate that the ligand for the new receptor is the retinoid, retinoic acid.Type: GrantFiled: January 11, 1994Date of Patent: August 20, 1996Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere
-
Patent number: 5534418Abstract: The present invention provides methods for the controlled production of recombinant proteins in cells. Cells employed in the invention method contain a gene encoding the desired recombinant protein, with transcription of the gene maintained under the control of a transcriptional control element which is activated by a ligand/receptor complex. The ligand/receptor complex is formed when a ligand (which is a hormone or/and analog thereof) is complexed with a receptor (which is a hormone receptor or functional analog thereof which has the transcription activating properties of the receptor). Receptor is produced by the expression of non-endogenous DNA which is also present in the cells used for production of recombinant protein.Type: GrantFiled: December 10, 1993Date of Patent: July 9, 1996Assignee: The Salk Institute for Biological StudiesInventors: Roland M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 5312732Abstract: The present invention provides substantially pure DNA's comprised of sequences which encode proteins having the hormone-binding and/or transcription-activating characteristics of a glucocorticoid receptor, a mineralocorticoid receptor, or a thyroid hormone receptor. The invention also provides various plasmids containing receptor sequences which exemplify the DNA's of the invention. The invention further provides receptor proteins, including modified functional forms thereof, expressed from the DNA's (or mRNA's) of the invention. In addition to the novel receptor DNA, RNA and protein compositions, the present invention involves a bioassay for determining the functionality of a receptor protein. By using our bioassay system we have discovered that a necessary and sufficient condition for activation of transcription of a gene (G), whose transcription is activated by hormones complexed with receptors, is the presence of the hormone and its receptor in the cell (C) where (G) is located.Type: GrantFiled: March 7, 1991Date of Patent: May 17, 1994Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 5298429Abstract: Bioassays are disclosed which are useful for determining whether a compound is a hormone receptor agonist (i.e., is capable of promoting the transcription-activation activities of such receptors) or a hormone receptor antagonist (i.e., is capable of blocking the transcription-activation activities of such receptors). The invention bioassay is conducted by culturing test cells in the presence of at least one compound whose ability to function as a ligand for said receptor protein (or functional engineered or modified forms thereof) is sought to be determined. Alternatively, test cells are cultured in medium containing increasing concentrations of at least one compound whose ability to inhibit the transcription activation activity of hormone receptor agonists is sought to be determined, and a fixed concentration of at least one agonist for the receptor protein.Type: GrantFiled: December 10, 1991Date of Patent: March 29, 1994Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Stanley M. Hollenberg, Vincent Giguere
-
Patent number: 5274077Abstract: A novel retinoic acid receptor is disclosed. The novel receptor is encoded for by CDNA carried on plasmid phRAR1, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera are constructed by exchanging functional domains between the glucocorticoid, the mineralocorticoid, the estrogen-related, the thyroid and the retinoic acid receptors. In addition, a novel method for identifying functional ligands for receptor proteins is disclosed. The method, which takes advantage of the modular structure of the hormone receptors and the idea that the functional domains may be interchangeable, replaces the DNA-binding domain of a putative novel receptor with the DNA-binding domain of a known receptor such as the glucocorticoid receptor. The resulting chimeric construction, when expressed in cells, produces a hybrid receptor whose activation of a ligand--(e.g.Type: GrantFiled: November 13, 1992Date of Patent: December 28, 1993Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere
-
Patent number: 5171671Abstract: A novel retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid phRAR1, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera are constructed by exchanging functional domains between the glucocorticoid, the mineralocorticoid, the estrogen-related, the thyroid and the retinoic acid receptors. In addition, a novel method for identifying functional ligands for receptor proteins is disclosed. The method, which takes advantage of the modular structure of the hormone receptors and the idea that the functional domains may be interchangeable, replaces the DNA-binding domain of a putative novel receptor with the DNA-binding domain of a known receptor such as the glucocorticoid receptor. The resulting chimeric construction, when expressed in cells, produces a hybrid receptor whose activation of a ligand-(e.g.Type: GrantFiled: August 6, 1990Date of Patent: December 15, 1992Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita S. Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Uemsono, Vincent Giguere
-
Patent number: 5071773Abstract: The present invention discloses two hormone receptor-related bioassays. The first bioassay is useful for determining whether a protein suspected of being a hormone receptor has transcription-activating properties of a hormone receptor. The second bioassay is useful for evaluating whether compounds are functional ligands for receptor proteins. According to the first bioassay, cells that contain non-endogenous DNA which expresses a protein suspected of being a hormone receptor and which contain a DNA sequence encoding an operative hormone responsive promoter/enhancer element linked to an operative reporter gene, are cultured, the culturing being conducted in a culture medium containing a known hormone, or an analog thereof. The cultured cells are then monitored for induction of the product of the reporter gene as an indication of functional transcription-activating binding between the hormone or hormone analog and the protein suspected of being a hormone receptor.Type: GrantFiled: October 20, 1987Date of Patent: December 10, 1991Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Cary A. Weinberger, Stanley M. Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine C. Thompson, Estelita S. Ong
-
Patent number: 4981784Abstract: A novel retinoic acid receptor is disclosed. The novel receptor is encoded for by cDNA carried on plasmid phRAR1, which has been deposited with the American Type Culture Collection for patent purposes. Chimeric receptor proteins are also disclosed. The chimera are constructed by exchanging functional domains between the glucocorticoid, the mineralocorticoid, the estrogen-related, the thyroid and the retinoic acid receptors. In addition, a novel method for identifying functional ligands for receptor proteins is disclosed. The method, which takes advantage of the modular structure of the hormone receptors and the idea that the functional domains may be interchangeable, replaces the DNA-binding domain of a putative novel receptor with the DNA-binding domain of a known receptor such as the glucocorticoid receptor. The resulting chimeric construction, when expressed in cells, produces a hybrid receptor whose activation of a ligand-(e.g.Type: GrantFiled: November 30, 1988Date of Patent: January 1, 1991Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, Estelita Ong, Prudimar S. Segui, Catherine C. Thompson, Kazuhiko Umesono, Vincent Giguere